Phase 2 significant effects. by Wendy C. Crone (2262169)

Phase 1 significant effects. by Wendy C. Crone (2262169)

Different steps of the fabrication process. by Md. Abu Daud (21485629)

“…XRD indicates that significant structural change had been taken place with the addition of ZrO₂. …”

1-MX significantly increases levels of neurotransmitters. by Ralf Jäger (35049)

Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)). by Mobina Faqani (22783963)

“…<p>Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).…”

Side effects of vaccination that affected participants’ children. by Sara Saleh (6733619)

Subjects:

Significant interactions from mixed linear models of ECM colonization (Table 1). by Laura García de Jalón (8939456)

Species richness decreases significantly with increasing percent disturbance. by Catherine L. Cardelús (6429320)

Linear regression. by Myriam Aïche (22290591)

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease). by Mobina Faqani (22783963)

“…<p>Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease).…”

Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

The results of threshold effect analysis. by Hai-bo Ai (20790405)

Subjects:

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects: